Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford Cancer Biomarkers Ltd.

www.oxfordcancerbiomarkers.com

Latest From Oxford Cancer Biomarkers Ltd.

Start-Up Quarterly Statistics, Q1 2012

Biopharma start-ups raised $338.1 million – 51% less than in Q4 2011. Device companies brought in $123.7 million and diagnostics firms raised $99.3 million; Series C rounds generated more money in both the device and diagnostic sectors than any other financing type. Cancer was the most prevalent therapeutic area for biopharma alliances. During Q1, M&As across biopharma and diagnostic industries were valued at a total of $471 million.

BioPharmaceutical Medical Device

Medical Device Deals Update, March 2012

A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.

Medical Device

Recent Tech Transfer Deals (03/2012)

START-UP’s monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical devices.

BioPharmaceutical Medical Device

Deals In Depth: January 2012

Forma Therapeutics penned an $815 million oncology drug discovery alliance with BI. BMS and Amgen spent over $1 billion each to purchase Inhibitex and Micromet, respectively. And AngioDynamics acquired Navilyst Medical for $367 million. Biopharma and device financing both increased in January from the previous month.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Oxford Cancer Biomarkers Ltd.
  • Senior Management
  • Glyn Edwards, CEO
    David Kerr, MD, CMO
  • Contact Info
  • Oxford Cancer Biomarkers Ltd.
    Phone: 7836 543 039
    co Isis Innovation, Ewert Pl. Summertown
    Ewert House
    Oxford, OX2 7SG
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register